前列腺癌患者睾酮替代治疗的安全性研究进展

Abstract
Figure/Table
References (28)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Hypogonadism in men is a clinical syndrome caused by androgen deficiency, for whom testosterone replacement therapy (TRT) is the preferred treatment.However, the use of TRT has been controversial in patients with a previous history of prostate cancer.In recent years, studies on the safety of TRT in patients with prostate cancer at different stages have been reported, including pre-cancerous stage, active surveillance, post-radical treatment and advanced prostate cancer.This article reviews the literatures and the progress in the application safety of TRT in patients with prostate cancer.

Key words： Prostate cancer Hypogonadism Testosterone Replacement therapy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Qi-bo
	ZHU Shao-xing

Cite this article:

WANG Qi-bo,ZHU Shao-xing. Research progress on the safety of testosterone replacement therapy in patients with prostate cancer[J]. 中国当代医药, 2020, 27(8): 16-18.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I8/16

[3]	J.Lisa TENOVER.老年男性的睾酮替代疗法[J].中华男科学，2001，7（3）：141-146.
[26]	NguyenTM，PastuszakAW.Testosteronetherapyamongprostate cancer survivors[J].Sex Med Rev，2016，4（4）：376-388.
[1]	Wang C，Nieschlag E，Swerdloff R，et al.Investigation，treatment and monitoring of late-onset hypogonadism in males：ISA，ISSAM，EAU，EAA and ASA recommendations[J].Eur J Endocrinol，2008，159（5）：507-514.
[2]	Glina S，Rivero MA，Morales A，et al.Studies on prostatic cancer I.The effect of castration，of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate by Charles Huggins and Clarence V.Hodges[J].J Sex Med，2010，7（2 Pt 1）：640-644.
[4]	Hoffman MA，DeWolf WC，Morgentaler A.Is low serum free testosterone a marker for high grade prostate cancer?[J].J Urol，2000，163（3）：824-827.
[5]	García-Cruz E，Piqueras M，Huguet J，et al.Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment[J].BJU Int，2012，110（11 Pt B）：E541-546.
[6]	Kim HJ，Kim BH，Park CH，et al.Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence[J].Korean J Urol，2012，53（1）：9-13.
[7]	Massengill JC，Sun L，Moul JW，et al.Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy[J].J Urol，2003，169（5）：1670-1675.
[8]	Merrimen JL，Jones G，Hussein SA，et al.A model to predict prostate cancer after atypical findings in initial prostate needle biopsy[J].J Urol，2011，185（4）：1240-1245.
[9]	Rhoden EL，Morgentaler A.Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer：results of 1 year of treatment in men with prostatic intraepithelial neoplasia[J].J Urol，2003，170（6 Pt 1）：2348-2351.
[10]	Kaufman JM，Graydon RJ.Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men[J].J Urol，2004，172（3）：920-922.
[11]	Agarwal PK，Oefelein MG.Testosterone replacement therapy after primary treatment for prostate cancer[J].J Urol，2005，173（2）：533-536.
[12]	Khera M，Grober ED，Najari B，et al.Testosterone replacement therapy following radical prostatectomy[J].J Sex Med，2009，6（4）：1165-1170.
[13]	Pastuszak AW，Pearlman AM，Lai WS，et al.Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy[J].J Urol，2013，190（2）：639-644.
[14]	Pastuszak AW，Khanna A，Badhiwala N，et al.Testosterone therapy after radiation therapy for low，intermediate and high risk prostate cancer[J].J Urol，2015，194（5）：1271-1276.
[15]	Sarosdy MF.Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy[J].Cancer，2007，109（3）：536-541.
[16]	Morales A，Black AM，Emerson LE.Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer：preliminary observations[J].BJU Int，2009，103（1）：62-64.
[17]	Pastuszak AW，Pearlman AM，Godoy G，et al.Testosterone replacement therapy in the setting of prostate cancer treated with radiation[J].Int J Impot Res，2013，25（1）：24-28.
[18]	Balbontin FG，Moreno SA，Bley E，et al.Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer[J].BJU Int，2014，114（1）：125-130.
[19]	Morgentaler A，Lipshultz LI，Bennett R，et al.Testosterone therapy in men with untreated prostate cancer[J].J Urol，2011，185（4）：1256-1260.
[20]	Kacker R，Hult M，San Francisco IF，et al.Can testosterone therapy be offered to men on active surveillance for prostate cancer？Preliminary results[J].Asian J Androl，2016，18（1）：16-20.
[21]	Fowler JE Jr，Whitmore WF Jr.The response of metastatic adenocarcinoma of the prostate to exogenous testosterone[J].J Urol，1981，126（3）：372-375.
[22]	Ferreira U，Leitao VA，Denardi F，et al.Intermittent androgen replacement for intense hypogonadism symptoms in castrated patients[J].Prostate Cancer Prostatic Dis，2006，9（1）：39-41.
[23]	Leibowitz RL，Dorff TB，Tucker S，et al.Testosterone replacement in prostate cancer survivors with hypogonadal symptoms[J].BJU Int，2010，105（10）：1397-1401.
[24]	Morgentaler A，Traish AM.Shifting the paradigm of testosterone and prostate cancer：the saturation model and the limits of androgen-dependent growth[J].Eur Urol，2009，55（2）：310-320.
[25]	Traish AM，Williams DF，Hoffman ND，et al.Validation of the exchange assay for the measurement of androgen receptors in human and dog prostates[J].Prog Clin Biol Res，1988，262：145-160.
[27]	Torres LO.Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer？ Opinion：YES[J].Int Braz J Urol，2018，44（1）：4-7.
[28]	Wroclawski ML，Heldwein FL.Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer？Opinion：Not Yet[J].Int Braz J Urol，2018，44（1）：8-13.